M&A Deal Summary

CSL Acquires Talecris Biotherapeutics Holdings Corp

On August 12, 2008, CSL acquired life science company Talecris Biotherapeutics Holdings Corp from Cerberus Capital Management and Ampersand Capital Partners for 3.1B USD

Acquisition Highlights
  • This is CSL’s 1st transaction in the Life Science sector.
  • This is CSL’s largest (disclosed) transaction.
  • This is CSL’s 1st transaction in the United States.
  • This is CSL’s 1st transaction in North Carolina.
Investment Fate
  • Talecris Biotherapeutics Holdings Corp was divested to a consortium of strategic buyers in 2011.

M&A Deal Summary

Date 2008-08-12
Target Talecris Biotherapeutics Holdings Corp
Sector Life Science
Buyer(s) CSL
Sellers(s) Cerberus Capital Management
Ampersand Capital Partners
Deal Type Add-on Acquisition
Deal Value 3.1B USD

Target

Talecris Biotherapeutics Holdings Corp

Research Triangle Park, North Carolina, United States
Talecris Biotherapeutics Holdings Corp. is a pharmaceutical Development and Manufacturing company.

Search 201,893 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

CSL

Melobourne, Australia

Category Company
Founded 1916
Sector Life Science
Employees32,698
Revenue 14.7B USD (2024)
DESCRIPTION

CSL is a manufacturer and marketer of pharmaceutical and diagnostic products, cell culture media and human plasma fractions. CSL was founded in 1916 and is based in Melbourne, Australia.


DEAL STATS #
Overall 1 of 2
Sector (Life Science) 1 of 2
Type (Add-on Acquisition) 1 of 1
State (North Carolina) 1 of 1
Country (United States) 1 of 1
Year (2008) 1 of 1
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2005-02-28 JRH Biosciences

Lenexa, United States

JRH, headquartered in Lenexa, Kansas, has major manufacturing facilities and/or serum collection and processing centers in Caseyville, Illinois, Lenexa, Kansas, and Denver, Pennsylvania in the United States; Andover in the United Kingdom; and Brisbane and Brooklyn in Australia. JRH's product lines include sera, cell culture media used in the production of therapeutic proteins, reagent growth factors and biological material containers. JRH has approximately 400 employees.

Sell $370M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2011-06-02 Talecris Biotherapeutics Holdings Corp

Research Triangle Park, North Carolina, United States

Talecris Biotherapeutics Holdings Corp. is a pharmaceutical Development and Manufacturing company.

Sell -

Seller(S) 2

SELLER

Cerberus Capital Management

New York, New York, United States

Investor Investor Investor Investor Investor


Category Asset Manager
Founded 1992
PE ASSETS 55.0B USD
Size Mega
Type Sector Agnostic
DESCRIPTION

Cerberus Capital Management is a private investment firm that targets a wide range of global investments. Cerberus primarily looks for undervalued or distressed situations. Industry sectors of interest include aerospace and defense, apparel, automotive and industrial, building products, commercial services, consumer and retail, financial services, healthcare, manufacturing and distribution, paper, packaging, and printing, real estate, technology, telecommunications, transportation, and travel. In addition to private equity investing, Cerberus also provides corporate credit and acquires real estate. Cerberus was formed in 1992 by Steve Feinberg and is based in New York City.


DEAL STATS #
Overall 4 of 54
Sector (Life Science) 1 of 3
Type (Add-on Acquisition) 1 of 27
State (North Carolina) 1 of 4
Country (United States) 3 of 36
Year (2008) 1 of 2
Size (of disclosed) 2 of 14
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2008-04-01 Advantage Resourcing America

Tokyo, Japan

Advantage is a member of a family of Staffing companies owned by parent Recruit Holdings Co., Ltd., based in Tokyo Japan. Advantage has offices in the U.S., Canada, UK and Sydney Australia. The Advantage service delivery model is “local market focus”, meaning that Advantage learns client requirements for primary skill sets in every local market we serve.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2008-10-17 Mervyn s

Hayward, California, United States

Mervyn's was a retail department store that was formed in 1949. The retail chain featured national brands and carried a broad selection of items - from apparel to electronics.

Sell -
SELLER

Ampersand Capital Partners

Wellesley, Massachusetts, United States

Investor Investor Investor Investor Investor


Category Growth Capital Firm
Founded 1988
PE ASSETS 3.0B USD
Size Large
Type Sector Focused
DESCRIPTION

Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.


DEAL STATS #
Overall 8 of 55
Sector (Life Science) 2 of 25
Type (Add-on Acquisition) 5 of 38
State (North Carolina) 2 of 4
Country (United States) 8 of 51
Year (2008) 1 of 1
Size (of disclosed) 1 of 13
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2008-01-23 Signature Genomic Laboratories

Spokane, Washington, United States

Signature Genomic Laboratories, LLC is a provider of microarray-based cytogenetic diagnostics with its proprietary SignatureChip and is the major in providing microarray-based chromosome analysis.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2008-08-29 MedVenture Technology

Jeffersonville, Indiana, United States

MedVenture Technology Corp. is a outsourced developer and manufacturer of disposable medical devices.

Buy -